Deep Track Capital, LP: ALNYLAM PHARMACEUTICALS INC (ALNY): Quarterly 13F Position History
As of Q2 2026, Deep Track Capital, LP reported 825,000 shares of ALNYLAM PHARMACEUTICALS INC (ALNY), worth $248.3M and representing 3.7% of its 13F equity book. Quarter-over-quarter share count change: + 825,000 (re-initiated) . The position first appeared in Q1 2022 and has been disclosed across 18 13F-HR filings in Pactolio's tracked window.
- 825,000Shares Held (Latest Filing)
- $248.3MReported Market Value (Latest Filing)
- 3.7%Portfolio Weight (% of 13F Equity Book)
- +825,000Quarter-over-Quarter Share Change
- +$248.3MQuarter-over-Quarter Value Change
- 832,310Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 18 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 825,000 | +825,000 | – | $248.3M | 3.7% | $301.0 |
| Q1 2026 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2024 | 0 | 500,000 | -100.0% | $0 | 0.0% | – |
| Q2 2024 | 500,000 | 332,310 | -39.9% | $121.5M | 3.6% | $243.0 |
| Q1 2024 | 832,310 | +832,310 | – | $124.4M | 3.6% | $149.4 |
| Q4 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2022 | 0 | 463,663 | -100.0% | $0 | 0.0% | – |
| Q1 2022 | 463,663 | – | – | $75.7M | 4.9% | $163.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Deep Track Capital, LP first disclose a ALNY position in 13F-HR filings?
Deep Track Capital, LP first reported ALNYLAM PHARMACEUTICALS INC (ALNY) on its 13F-HR filing for the period ending 2022-03-31 (Q1 2022). The position has appeared on 18 reported quarters within Pactolio's tracked window.
What was Deep Track Capital, LP's most recent quarter-over-quarter share-count change in ALNY?
Between Q1 2026 and Q2 2026, Deep Track Capital, LP added 825,000 shares of ALNY (re-initiated), bringing the total reported position to 825,000 shares at a market value of $248.3M.
Does the implied price-per-share represent Deep Track Capital, LP's cost basis in ALNY?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.